Samantha Bruno

Bologna, 40138, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets.

Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets.

Journal: International journal of molecular sciences

Published: July 30, 2024

Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia.

Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia.

Journal: Nature communications

Published: October 01, 2023

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.

Journal: Biomarker research

Published: December 15, 2022

Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor Cells.

Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor Cells.

Journal: Stem cells (Dayton, Ohio)

Published: December 15, 2022

Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.

Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.

Journal: Leukemia

Published: March 24, 2022

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors.

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors.

Journal: Frontiers in oncology

Published: March 21, 2022

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies.

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies.

Journal: Journal of experimental & clinical cancer research : CR

Published: January 14, 2022

Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.

Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.

Journal: Cancers

Published: December 13, 2021

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.

Journal: OncoTargets and therapy

Published: November 10, 2021

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.

Journal: Frontiers in oncology

Published: June 21, 2021

Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?

Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?

Journal: International journal of molecular sciences

Published: May 29, 2021

Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.

Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.

Journal: Mediterranean journal of hematology and infectious diseases

Published: May 26, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026